Mission Statement, Vision, & Core Values (2026) of C.Q. Pharmaceutical Holding Co., Ltd.

Founded in the early 2000s, C.Q. Pharmaceutical Holding Co., Ltd. (000950.SZ) has built a vertically integrated business model-spanning discovery, development, manufacturing and marketing-that underpins its portfolio of generic medications and proprietary treatments across antibiotics, cardiovascular and oncology areas, a strategy that supports its mission to deliver reliable, affordable medicines and its vision to become a global leader in accessible, high-quality healthcare; guided by core values-care for life, sustainable innovation, excellence and partnership-the company has expanded exports and global partnerships and, as of late 2025, continues to prioritize R&D, quality control and corporate social responsibility to reduce patient cost burdens and extend access to essential therapies worldwide.

C.Q. Pharmaceutical Holding Co., Ltd. (000950.SZ) - Intro

• Corporate footprint: integrated R&D, formulation and API production, quality assurance, regulatory affairs and domestic/international commercial teams.
• Product scope: broad therapeutic mix including anti-infectives, cardiovascular, oncology, metabolic and specialty hospital drugs.
• Global reach: exports to multiple regions and strategic partnerships with several international distributors and healthcare organizations.

• Provide safe, effective and affordable medicines that address key unmet needs in China and global markets.
• Deliver consistent quality through end-to-end control of the pharmaceutical value chain.
• Drive sustainable growth that balances shareholder returns with public health impact.

• Become a globally recognized innovator and supplier of high-quality pharmaceuticals rooted in rigorous R&D and scalable manufacturing.
• Expand international market share while deepening therapeutic expertise in priority disease areas.

• Quality first - uncompromising compliance with GMP, regulatory and safety standards.
• Innovation - sustained investment in R&D and translational science.
• Patient focus - accessibility and affordability for underserved populations.
• Integrity and transparency - ethical business conduct and stakeholder accountability.
• Sustainability - responsible manufacturing, supply continuity and community health engagement.

• Pipeline strategy blends lifecycle management of established molecules with targeted R&D in oncology, cardiovascular and anti-infective agents.
• Investments prioritize analytical development, formulation upgrades and bioequivalence/clinical studies to support domestic and international registrations.
• Collaborations with academic institutions and contract research organizations to accelerate translational programs and regulatory dossiers.

• End-to-end quality systems aligned to national GMP; continuous improvement programs to reduce batch deviations and improve yields.
• Supply-chain diversification to mitigate raw-material risks and ensure continuity for hospital and retail channels.
• Environmental and safety controls embedded in manufacturing expansion plans to meet evolving regulatory expectations.

• Programs to improve access to affordable medicines in underserved regions, including patient assistance and pricing strategies for essential medicines.
• Health-education initiatives and local community partnerships focused on disease prevention and rational medicine use.

• Scale international registrations and distribution partnerships to grow export revenue share.
• Increase R&D productivity through focused therapeutic portfolios and acquisition/partnerships where appropriate.
• Optimize capital allocation to expand high-efficiency production capacity and upgrade quality systems.
• Enhance investor transparency and corporate governance to support longer-term valuation uplift.

C.Q. Pharmaceutical Holding Co., Ltd. (000950.SZ) - Overview

• Mission: Provide cost-effective, high-quality generic alternatives to brand-name drugs to enhance access and sustainability of healthcare worldwide.
• Vision: To be a globally recognized leader in affordable pharmaceuticals, trusted for consistent quality, broad therapeutic coverage, and responsible expansion into underserved markets.
• Core Values: Patient-first quality, regulatory compliance, affordability, supply reliability, continuous improvement, and responsible corporate citizenship.

• Quality & Compliance: Investments in GMP-compliant facilities, routine third-party testing, and pharmacovigilance to maintain trust with payers and prescribers.
• Affordability: Pricing frameworks and product mix designed to lower out-of-pocket costs for patients and reduce procurement spend for healthcare providers.
• Access & Distribution: Strategic domestic and international channels to reach regions with constrained healthcare budgets.

C.Q. Pharmaceutical Holding Co., Ltd. (000950.SZ) - Mission Statement

• Accessibility: expand reach to serve patients in 80+ countries and regions by 2030, with prioritized distribution channels in Southeast Asia, Africa, Latin America, and emerging markets in Eastern Europe.
• Quality: maintain regulatory approvals and GMP standards across 100% of production sites; target product defect/recall rates below 0.01% annually.
• Patient-centered impact: aim to improve adherence and outcomes by designing at least 50 new patient-support programs and digital adherence tools by 2028.

• Manufacturing scale-up: modular capacity increases to cut lead times by 30% and support 2-3x production for prioritized generics and specialty products.
• Regulatory & quality assurance: cross-border regulatory teams to pursue approvals (e.g., WHO PQ, EU, US ANDA/MAA where applicable) to facilitate export expansion.
• Partnerships & access: licensing, tiered pricing, and NGO collaboration to lower patient prices and extend distribution into low-resource settings.

• Contributing to essential-medicine availability - addressing part of the ~2 billion people lacking access by focusing on high-burden conditions in target regions.
• Supporting affordability - deploying tiered pricing, generics scale, and cost-efficient manufacturing to make treatments more affordable for low- and middle-income populations.
• Improving outcomes - integrating patient education and digital adherence tools to measurably improve treatment completion and clinical outcomes.

C.Q. Pharmaceutical Holding Co., Ltd. (000950.SZ) - Vision Statement

Core values anchor strategy and daily operations, shaping decisions from pipeline prioritization to partner selection. These values are lived through measurable actions across R&D, manufacturing, commercial deployment and collaboration.

• Care for life - prioritizing patient outcomes and safety across all product lines and clinical programs.
• Continuous pursuit of sustainable innovation - investing in research and green manufacturing to deliver novel, eco-conscious therapies.
• Excellence - maintaining high standards in quality control, regulatory compliance and customer service.
• Partnership - forging long-term collaborations with healthcare providers, academic institutions and supply-chain partners.

'Care for life' places patients at the center of corporate purpose: clinical trial design, post-market surveillance, and access programs reflect this orientation. The company's R&D and manufacturing practices are calibrated to reduce environmental impact while ensuring therapeutic efficacy and safety.

These figures illustrate how the company channels resources toward innovation, quality and sustainable operations that reflect its core values.

• R&D focus areas: cardiovascular, metabolic, oncology-supportive care and high-value generics.
• Sustainability initiatives: energy efficiency upgrades, reduction of solvent waste, and green chemistry adoption in selected processes.
• Partnership model: co-development with academic centers, licensing agreements for regional commercialization, and long-term supply contracts with strategic vendors.

Operational metrics tied to the vision and values include adherence to international GMP, ongoing expansion of clinical development capabilities, and a measurable increase in R&D pipeline assets year-over-year. For deeper financial context and investor-oriented analysis, see: Breaking Down C.Q. Pharmaceutical Holding Co., Ltd. Financial Health: Key Insights for Investors